IMCD Acquires Trichem to Strengthen Pharmaceutical Supply Chain in India's Generic Drug Market
核心洞察
IMCD N.V. (搜索) has acquired 100% of Trichem Healthcare Private Limited (搜索) and its subsidiaries to expand its pharmaceutical distribution capabilities in India and the Middle East.
Trichem, founded in 1998 and based in Mumbai, generates approximately INR 1.7 billion (EUR 18 million) annually through supplying active pharmaceutical ingredients (搜索) and pharmaceutical intermediates (搜索).
The acquisition positions IMCD to capitalize on India's role as a major supplier of generic drugs (搜索) globally while adding regulatory expertise for highly regulated pharmaceutical markets.
IMCD N.V. (搜索), a global specialty chemicals distributor, has completed the acquisition of 100% of shares in Trichem Healthcare Private Limited (搜索), Trichem Lifesciences Limited (搜索), and Chemistry & Health FZ LLC, strengthening its position in India's pharmaceutical supply chain. The acquisition was announced on June 26, 2025, as part of IMCD's strategy to expand its pharmaceutical market presence in the region.
Strategic Expansion in India's Pharmaceutical Sector
Founded in 1998 and headquartered in Mumbai, Trichem has established a strong reputation in the healthcare sector over 27 years of operations. The company specializes in supplying high-quality active pharmaceutical ingredients (搜索), pharmaceutical intermediates (搜索), and formulation solutions across India and the Middle East. With 36 employees, Trichem generated annual revenue of approximately INR 1.7 billion (EUR 18 million) for the financial year ended March 31, 2025, with about 33% of revenue derived from commission income.
"With India being a major supplier of the world's generic drugs (搜索), this acquisition further enhances our portfolio, in particular with active pharmaceutical ingredients (搜索), and reinforces our position in the region's life-sciences industry," said Narendra Varde, Managing Director of IMCD India. The acquisition adds regulatory assistance capabilities for customers serving India's highly regulated pharmaceutical markets.
Industry Leadership and Market Position
IMCD, based in Rotterdam, The Netherlands, operates as a leading global partner for the distribution and formulation of specialty chemicals and ingredients. In 2024, the company employed over 5,100 professionals and realized revenues of EUR 4,728 million. IMCD N.V. (搜索)'s shares are traded on Euronext Amsterdam under the symbol IMCD and are included in the Dutch ESG AEX index as one of 25 companies demonstrating best ESG practices.
Chetan Jain, Founder and Promoter of Trichem Group, expressed confidence in the partnership: "IMCD and Trichem share a common vision, strong entrepreneurial spirit, and commitment to building lasting partnerships. I am extremely proud of Trichem's achievements over the past 27 years. Going forward with IMCD's global presence, and our strong global principal partnerships, I am confident that this business will deliver immense value to our stakeholders."
Enhanced Pharmaceutical Distribution Capabilities
The acquisition brings together Trichem's deep market expertise and strong industry relationships with IMCD's global presence and principal partnerships. This combination is expected to strengthen IMCD's ability to serve the pharmaceutical industry in India, a critical market for generic drug manufacturing and distribution globally. The integration adds specialized knowledge in navigating India's regulatory environment for pharmaceutical products.